Post- marketing alvorlige spontane bivirkningsrapporter efter behandling med palivizumab som dækker fire RSV sæsoner mellem 1998 og 2002 er blevet evalueret.
Post-marketing serious spontaneous adverse events reported during palivizumab treatment between 1998 and 2002 covering four RSV seasons were evaluated.